# EDGAR Filing Document

**Accession Number:** 0000714256
**File Stem:** 0001493152-25-021615
**Filing Date:** 2025-11
**Character Count:** 10084
**Document Hash:** cd85742f4b95942c7546399d0c3ea348
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-021615.hdr.sgml**: 20251112

**ACCESSION NUMBER**: 0001493152-25-021615

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20251111

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251112

**DATE AS OF CHANGE**: 20251112

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sanara MedTech Inc.
- **CENTRAL INDEX KEY:** 0000714256
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 592220004
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39678
- **FILM NUMBER:** 251468256

**BUSINESS ADDRESS:**
- **STREET 1:** 1200 SUMMIT AVE
- **STREET 2:** SUITE 414
- **CITY:** FORT WORTH
- **STATE:** TX
- **ZIP:** 76102
- **BUSINESS PHONE:** 817-529-2300

**MAIL ADDRESS:**
- **STREET 1:** 1200 SUMMIT AVE
- **STREET 2:** SUITE 414
- **CITY:** FORT WORTH
- **STATE:** TX
- **ZIP:** 76102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WOUND MANAGEMENT TECHNOLOGIES, INC.
- **DATE OF NAME CHANGE:** 20080611

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MB SOFTWARE CORP
- **DATE OF NAME CHANGE:** 19960805

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INAV TRAVEL CORPORATION
- **DATE OF NAME CHANGE:** 19920703

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **November 11, 2025**

---

| |
|:---|
| **SANARA MEDTECH INC.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Texas** | **001-39678** | **59-2219994** |
| (State or other jurisdiction of | (Commission | (IRS Employer |
| incorporation) | File Number) | Identification No.) |

---

---

| | |
|:---|:---|
| **1200 Summit Avenue, Suite 414** <br> **Fort Worth, Texas** | **76102** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(817) 529-2300**

(Former name or former address, if changed since last report)

**Not Applicable**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value | SMTI | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 2.02** | **Results of Operations and Financial Condition.** |

---

On November 11, 2025, Sanara MedTech Inc. (the "Company") issued a press release announcing that it has initiated a strategic realignment of its business, discontinuing operations of its Tissue Health Plus. A copy of the Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

**(d) Exhibits** 

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release issued November 11, 2025 (furnished pursuant to Item 2.02).](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date: | November 12, 2025 |  |  |
|  |  | **Sanara MedTech Inc**. | **Sanara MedTech Inc**. |
|  |  | By: | */s/ Elizabeth B. Taylor* |
|  |  | Name: | Elizabeth B. Taylor |
|  |  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Sanara MedTech Inc. Announces Strategic Realignment to Focus on Surgical Business**

*Completes Evaluation of Strategic Alternatives for Tissue Health Plus Segment* 

FORT WORTH, TX, November 11, 2025 (GLOBE NEWSWIRE) - **Sanara MedTech Inc.** ("Sanara," the "Company," "we," "our" or "us") (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that the Company completed its previously announced evaluation of strategic alternatives for Tissue Health Plus ("THP"). Following the completion of this evaluation, the Company initiated a strategic realignment of its business, discontinuing operations of THP to improve its operating efficiency and reallocate resources to its core surgical business.

"After reviewing strategic alternatives for THP, Sanara's management and Board of Directors decided to cease development efforts on the THP platform in late September and discontinue THP's operations to allocate resources to Sanara's surgical business, which we believe has the greatest potential to deliver sustainable, long-term growth and value to our shareholders," stated Seth Yon, Sanara's President and Chief Executive Officer. "Sanara's surgical business has demonstrated an impressive track record of consistent net revenue growth over the past several years. We believe these results highlight the strength of our surgical products, team capabilities, and go-to-market strategy."

Mr. Yon continued, "With this in mind, the strategic realignment being announced today is intended to allow Sanara to allocate capital toward opportunities with the highest expected returns. These activities will be discussed further during our third quarter earnings call tomorrow morning."

As a result of the Company's strategic realignment, the operations of THP, which were previously reported as the THP segment, will be classified as discontinued operations in Sanara's financial statements going forward in accordance with generally accepted accounting principles in the United States. The process of winding down THP is expected to continue through the end of 2025. The Company continues to expect that the total cash investment in THP will range from $5.5 million to $6.5 million in the second half of 2025. The Company does not expect to have material cash expenses related to THP after year-end.

** 

**About Sanara MedTech Inc.**

Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. The Company develops, markets, and distributes surgical products for use by physicians and clinicians in hospitals. Each of the Company's products, services, and technologies are designed to achieve the goal of providing better clinical outcomes at a lower overall cost for patients. Sanara's products are primarily sold in the North American surgical tissue repair markets. Sanara markets and distributes CellerateRX® Surgical Activated Collagen® Powder, BIASURGE® Advanced Surgical Solution, FORTIFY TRG® Tissue Repair Graft, FORTIFY FLOWABLE® Extracellular Matrix, as well as a portfolio of advanced biologic products including: ACTIGEN® Verified Inductive Bone Matrix, ALLOCYTE® Plus Advanced Viable Bone Matrix, BiFORM® Bioactive Moldable Matrix, and TEXAGEN® Amniotic Membrane Allograft to the surgical market. The Company believes it can drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. The Company strives to be one of the most innovative and comprehensive providers of effective surgical solutions and is continually seeking to expand its offerings for patients requiring treatments in the United States. For more information, please visit <u>SanaraMedTech.com</u>.

**Information about Forward-Looking Statements**

All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.

**Investor Relations Contact:**

Jack Powell or Mike Piccinino, CFA

ICR Healthcare

<u>IR@sanaramedtech.com</u>